Health Care & Life Sciences » Pharmaceuticals | Shield Therapeutics PLC

Shield Therapeutics PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,550.00
477.00
725.00
20,978.00
13,299.00
9,776
Total Accounts Receivable
20.00
28.00
96.00
1,058.00
529.00
1,962
Inventories
-
-
-
418.00
125.00
109
Other Current Assets
81.00
51.00
1,509.00
927.00
1,043.00
569
Total Current Assets
1,651.00
556.00
2,330.00
23,381.00
14,996.00
12,416
Net Property, Plant & Equipment
5.00
12.00
17.00
19.00
13.00
8
Intangible Assets
387.00
436.00
513.00
28,984.00
29,961.00
30,957
Total Assets
2,043.00
1,004.00
2,860.00
52,384.00
44,970.00
43,381
ST Debt & Current Portion LT Debt
7,093.00
8,258.00
-
-
-
Accounts Payable
-
-
-
1,490.00
1,802.00
Other Current Liabilities
955.00
744.00
3,575.00
2,498.00
1,961.00
Total Current Liabilities
8,048.00
9,002.00
3,575.00
3,988.00
3,763.00
Long-Term Debt
-
197.00
-
-
-
Other Liabilities
1,312.00
10,089.00
17,928.00
-
-
Total Liabilities
9,360.00
19,288.00
21,503.00
3,988.00
3,763.00
Common Equity (Total)
8,064.00
20,030.00
18,643.00
48,396.00
41,207.00
Total Shareholders' Equity
8,064.00
20,030.00
18,643.00
48,396.00
41,207.00
Total Equity
7,317.00
18,284.00
18,643.00
48,396.00
41,207.00
Liabilities & Shareholders' Equity
2,043.00
1,004.00
2,860.00
52,384.00
44,970.00
Accumulated Minority Interest
747.00
1,746.00
-
-
-

About Shield Therapeutics

View Profile
Address
Northern Design Centre
Gatehead Quays GH NE8 3DF
United Kingdom
Employees -
Website http://shieldtherapeutics.com
Updated 07/08/2019
Shield Therapeutics Plc is a pharmaceutical company. It engages in the development and commercialization of secondary care focused pharmaceuticals. Its products include Feraccru, which treats oral problems with iron deficiency anaemia; and PT20, which treats hyperphosphatemia.